• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • 0 CME Hours
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Alerts

Aspirin Treatment for Women at Risk for Preeclampsia – ACOG and USPSTF Recommendations  

image_pdfFavoriteLoadingFavorite

FINDINGS:

ACOG and SMFM have released guidance, stating that they “support the USPSTF guideline criteria for prevention of preeclampsia” on the use of low-dose aspirin during pregnancy to prevent preeclampsia.  When indicated, low-dose aspirin should be started between 12 to 28 weeks and continued until delivery.  Optimally, aspirin usage should begin <16 weeks.

Recommended (high risk)

  • Offer low-dose aspirin (81 mg/day) to women with ≥1 high risk factors for preeclampsia, which include
    • History of preeclampsia, especially if accompanied by an adverse outcome
    • Multifetal gestation
    • Chronic hypertension
    • Diabetes (Type 1 or Type 2)
    • Renal disease
    • Autoimmune disease (for example, systematic lupus erythematosus, antiphospholipid syndrome)

Consider Prophylaxis (moderate risk)

  • Offer low-dose aspirin (81 mg/day) to women with >1 moderate risk factors for preeclampsia, which include
    • Nulliparity
    • Obesity (BMI >30)
    • Personal history
      • low birthweight or SGA
      • Previous adverse pregnancy outcome
    • Family history of preeclampsia
      • Sister or mother
    • Social and demographic characteristics
      • African American race | low socioeconomic status
    • Maternal age ≥35 years
    • >10 year interpregnancy interval

Not Recommended Without Preeclampsia Risk Factors

  • Low risk: Previous uncomplicated full-term delivery
  • Insufficient Evidence
    • Prior unexplained stillbirth (insufficient evidence)
    • Prevention of fetal growth restriction
    • Prevention of spontaneous PTB
  • No Benefit
    • Prevention of early pregnancy loss

USPSTF Guidance

  • The systematic review (Ann Intern Med, 2014), performed on behalf of the USPSTF, demonstrated the following benefits of low-dose aspirin for women at risk for preeclampsia
    • 14% risk reduction for preterm birth (< 37 weeks)
    • 20% risk reduction for IUGR
    • Increase in average birthweight of 130 g
    • 24% risk reduction for preeclampsia
    • Only 1 paper had follow up (18 months) on children; no developmental harms were identified
  • Harms
    • No harms from low-dose aspirin were identified, however some events were sufficiently rare that possible negative outcomes from aspirin use, such as abruption, cannot be completely ruled out
  • USPSTF updated recommendations
    • The USPSTF recommends screening for preeclampsia in pregnant women with blood pressure measurements throughout pregnancy (‘B’ grade’ – offer or provide this service)
    • The USPSTF recommends providers offer low-dose aspirin to women at high risk for preeclampsia (‘B’ grade’ – offer or provide this service)

KEY POINTS:

  • The USPSTF states that “the harms of low-dose aspirin in pregnancy are considered to be no greater than small”
  • Risk factors used for ACOG/SMFM recommendations only include factors obtained from the medical record
    • Uterine artery Doppler ultrasonography and biochemical markers are not included
    • ACOG/SMFM acknowledge that other studies, in particular the ASPRE trial (see ‘Related ObG Topics’ below), have incorporated ultrasound and maternal serum markers as well as doses >81 mg, but state

Further, the screening algorithm used includes first-trimester serum markers, including placental growth factor and pregnancy-associated plasma protein-A, as well as uterine artery dopplers, which limits the generalizability to a U.S. population. Therefore, a higher dose or doubling of the available 81-mg dose cannot be recommended at this time.

Screening for Preeclampsia

  • Various studies have incorporated not only clinical risk factors but also biochemical markers and ultrasound to determine which women are at risk for early onset preeclampsia and may benefit from aspirin prevention (see ‘Related ObG Topics’)
  • ACOG considers the supporting data for the use of such combined risk assessment algorithms to be limited and without more prospective clinical utility trials, states that

…biomarkers and ultrasonography cannot accurately predict preeclampsia and should remain investigational.

Learn More – Primary Sources:

ACOG Practice Bulletin 222: Gestational Hypertension and Preeclampsia 

Low-Dose Aspirin for Prevention of Morbidity and Mortality From Preeclampsia: A Systemic Evidence Review for the U.S. Preventive Services Task Force (PDF)

USPSTF: Screening for Preeclampsia

ACOG/SMFM Committee Opinion 743: Low-Dose Aspirin Use During Pregnancy

Want to be notified when new guidelines are released? Get ObGFirst!

Learn More »

image_pdfFavoriteLoadingFavorite

< Previous
All Alerts Posts
Next >

Related ObG Topics:

Diagnosing Preeclampsia – Key Definitions and ACOG Guidelines
Does Aspirin Decrease the Risk of Preterm Birth in Preeclampsia?
ASPRE Trial: A Combined Risk Algorithm and Use of Aspirin to Prevent Preterm Preeclampsia
Does Enoxaparin Prevent Preeclampsia?
When to Introduce Aspirin to Reduce Risks of Preeclampsia?
ISUOG Recommendations for Preeclampsia Prevention: Combined Screening and the Role of Ultrasound
FIGO First Trimester Preeclampsia Screening Guidelines: Prevention Using Clinical Information and Biomarkers
Consensus Statement: Screening for Early-Onset Preeclampsia and Aspirin Prophylaxis in the US

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • #Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

ObG Library

  • Hysteroscopy
  • Fertility
  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Log In to ObG First

Please log in to access OBGFirst and the 2T Ultrasound Atlas

Password Trouble?

Sign Up for ObGFirst

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!

ObG First Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site